Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

230 targets multiple subtypes of the receptor for somatostatin (sst), a hormone that controls the pituitary gland. Its highest affinity is to sst5, a receptor subtype frequently expressed by the pituitary tumors associated with Cushing's disease. Currently approved somatostatin analogs preferentially bind to sst2 and are not effective in Cushing's disease(6).

SOM230 is currently being studied as a twice-daily sc injection, as well as a long-acting release (LAR) once-monthly intramuscular injection for the treatment of multiple disease types, including Cushing's disease, carcinoid syndrome and acromegaly(10).

Because it is an investigational compound, the safety and efficacy profile of SOM230 has not yet been established. Access to this investigational compound is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. There is no guarantee that SOM230 will become commercially available(6).

Information about Novartis clinical trials for SOM230 can be obtained by healthcare professionals at www.pasporttrials.com.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," "potential," or similar expressions, or by express or implied discussions regarding regulatory submissions or approvals for SOM230, or the timing of such submissions or approvals, or regarding potential future revenues from SOM230. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with SOM230 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guar
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Ltd. (NASDAQ: SVA ), a leading provider of biopharmaceutical ... of the Company,s 2014 Annual General Meeting of Shareholders held on ... The required quorum, a majority of the common shares outstanding, was ... following proposals:  , The re-election of Weidong Yin ... Kenneth Lee and Meng Mei as the Company,s ...
(Date:8/27/2014)... YORK and LONDON , Aug. 27, ... research solutions, MarketResearch.com is pleased to announce the ... Medical Devices Knowledge Center. The Medical ... the latest market research in the healthcare industry. ... reports from industry expert, Kalorama Information, published from ...
(Date:8/26/2014)... -- Intelomed is pleased to announce that Mary ... the Vice President of Clinical Affairs. With over 30 ... industry, Kay,s experience in taking medical technology and associated ... global expansion, is a valuable addition to the Intelomed ... our team, and I am confident her focused and ...
Breaking Medicine Technology:Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3Mary Kay Deck joins Intelomed as Vice President of Clinical Affairs 2
(Date:8/27/2014)... Aug. 27, 2014 (HealthDay News) -- A new genetic ... to fight the bowel disorder, researchers report. ... that affect how their genes work, and said these ... with raising the possibility of a simple diagnostic test ... the disease develops and suggest possible gene targets for ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 The ... the recipients of the 2014-2016 Basic Research Fellowships and ... career scientists, the ABTA is seeding the field with ... change our understanding of the causes, effects, diagnosis and ... by a scientific committee based on the potential to ...
(Date:8/27/2014)... According to a new market ... Market (Applications: Cardiovascular, Gynecology, Pain Management, Oncology, Urology, ... - Global Industry Analysis, Size, Share, Growth, Trends ... technologies market was valued at USD 4,698 million ... market worth USD 10,611 million in 2020 at ...
(Date:8/27/2014)... Disability (CLD) has received a two-year, $600,000 grant ... the Health Resources and Services Administration to support ... at improving services for children and youth with ... project, CLD worked with an Autism Advisory Council ... resulting plan addresses priorities of increased awareness of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Representatives with ... added Italy to its list of destinations for International ... for Recharge Retreats, explained that the company chose Italy ... destination for yoga teacher trainings since it's an easy ... journey for people traveling from all over Europe, UK, ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 2Health News:Recharge Retreats Adds Italy to Its International Yoga Teacher Trainings Destinations 3
... ,KO Cancer, with Susan G. Komen for the Cure, ... boxers,Felix "Tito" Trinidad and Roy Jones Jr. -- who will ... Jan. 19 -- have teamed with Susan G.,Komen for the ... activists, to help educate and raise awareness regarding the,deadly disease., ...
... diagnostic imaging, BLOOMINGTON, Minn., Dec. 21 ... efficiency of care reduced,medical expenses by $74 million ... introduced in February, reduced unnecessary,tests by more than ... from the American College of Radiology to confirm ...
... BROOK, Ill. December 21, 2007 The ... for the role of endoscopy in treating dyspepsia, discomfort ... a fourth of the population in Western countries. ... instrument to evaluate the inside of the esophagus, stomach ...
... for 2007, CONCORD, Ontario, Dec. 21 ... ,OTG, ,the Company,), a,leading multi- industry computer hardware, ... received an order for 100TB SAN dedicated,to pioneering ... oncology hospitals. The EqualLogic iSCSI SAN order is ...
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... by Dr. Steve Bailey, an internationally recognized sports historian, ... the beginnings, achievements and events that shaped the Paralympic ... Movement and other able-bodied sports. , In addition ... First establishes key players in administration and sports politics, ...
Cached Medicine News:Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 2Health News:Don King Enlists Prizefighters Felix 'Tito' Trinidad and Roy Jones Jr. to Strike a Blow against Breast Cancer 3Health News:HealthPartners Reports 2007 Most Cost Effective Programs Reduce Expenses by $74 Million 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 2Health News:ASGE offers guidelines on endoscopic treatment of dyspepsia 3Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 2Health News:On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects 3Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:First reputable book on the history of the Paralympic Movement 2
IDS Rapid NF Plus, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Bax detection system is a fast and accurate test for screening food and environmental samples by breaking them down to genetic level, using the power of the polymerase chain reaction (PCR) to detect ...
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
Medicine Products: